SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
March 18, 1996
XYTRONYX, INC.
-----------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE
--------------------------
(State or other jurisdiction of incorporation
0-14838 36-3258753
------------------------- ------------------------------
(Commissioner File Number) (IRS Employer Identification Number)
6555 Nancy Ridge Drive
Suite 200
San Diego, California 92121
-----------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (619) 550-3900
Item 5. OTHER EVENTS.
The News Release dated March 18, 1996 regarding completion of the U.S.
clinical studies of its Periodontal Tissue Monitor, filed as Exhibit 99.48
hereto, is hereby incorporated into this Report by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) EXHIBITS. The following exhibit accompanies this Report:
EXHIBIT
NUMBER EXHIBIT DESCRIPTION
99.48 News Release dated March 18, 1996 regarding completion of the
U.S. clinical studies of its Periodontal Tissue Monitor.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
XYTRONYX, INC.
By: /s/ DALE SANDER
---------------------------
Dale Sander
Chief Financial Officer
Date: March 22, 1996
2
INDEX TO EXHIBITS
EXHIBIT SEQUENTIALLY
NUMBER DESCRIPTION OF EXHIBIT NUMBERED PAGE
99.48 News Release dated March 18, 1996 regarding completion of the U.S.
clinical studies of its Periodontal Tissue Monitor.
3
FOR IMMEDIATE RELEASE
CONTACT: Dale A. Sander, Chief Financial Officer
Larry O. Bymaster, Chief Executive Officer
(619) 550-3900
------------------------------------------------------------------------------
XYTRONYX, INC. ANNOUNCES COMPLETION OF
CLINICAL STUDIES FOR PERIODONTAL TISSUE MONITOR
SAN DIEGO, CA, March 18, 1996 -- Xytronyx, Inc. (AMEX: XYX) today announced that
it has completed the U.S. clinical studies of its Periodontal Tissue Monitor
(the "PTM"). Xytronyx stated that it has begun the process of summarizing and
evaluating the data from the clinical studies, and will include the data and
other required information in a Premarket Application expected to be filed with
the U.S. Food and Drug Administration by mid-year.
The PTM is designed to assist periodontists and dentists with the evaluation and
monitoring the effectiveness of treatment of periodontitis, a serious form of
gum disease. The U.S. clinical studies involved testing a total of
approximately 175 patients and control subjects with the PTM over a 12-month
period. The studies were performed at three universities, Harvard University,
the University of North Carolina, and the University of Washington.
4